Advanced Ovarian Cancer clinical trials

Explore recruiting advanced ovarian cancer clinical trials.

Recruiting advanced ovarian cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Ovarian Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

Belgium, Italy, Spain, France, Finland, Bulgaria +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Combined treatment of intraperitoneal chemotherapy after optimal interval surgery in advanced ovarian cancer

Spain

Therapeutic use (Phase IV) EU CTIS Study details

CATALINA-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (CLDN6)

Ireland, Belgium, Austria, France, Germany, Spain +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

Hungary, Spain, Belgium, Czechia, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Poland, Spain, Netherlands, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Advanced Ovarian Cancer trials by city

Advanced Ovarian Cancer clinical trials

Recruiting advanced ovarian cancer studies right now

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

SEQUENTIAL PROFILING OF TUMOR-DERIVED CIRCULATING CELL-FREE DNA (ctDNA) IN ADVANCED OVARIAN CANCER PATIENTS

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Also recruiting in Europe

Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

Combined treatment of intraperitoneal chemotherapy after optimal interval surgery in advanced ovarian cancer

CATALINA-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (CLDN6)

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Advanced Ovarian Cancer trials by city

Other conditions